Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: Gilead is a biopharmaceutical company focused on HIV, viral hepatitis, COVID-19, and cancer. The company operates globally with headquarters in Foster City, California.
Key Financial Metrics
| Metric (in millions) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $6,954 | $6,599 | $13,640 | $12,951 |
| Net Income (Loss) Attributable to Gilead | $1,614 | $1,045 | $(2,556) | $2,055 |
| Diluted EPS | $1.29 | $0.83 | $(2.05) | $1.63 |
| Operating Income (Loss) | $2,644 | $1,665 | $(1,678) | $3,370 |
| Product Gross Margin | 77.7% | 78.0% | 77.2% | 77.9% |
| Cash and Cash Equivalents (End of Period) | $2,772 | $5,704 | $2,772 | $5,704 |
| Total Debt (Net) | $23,349 | $24,987 | $23,349 | $24,987 |
Note: YTD 2024 Net Loss is significantly impacted by non-recurring charges detailed below.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5% year-over-year for both the quarter and the six-month period, driven by higher sales in HIV (Biktarvy), Oncology (Trodelvy, Yescarta), and Liver Disease.
- Q2 Profitability: Q2 2024 net income rose 55% to $1.6 billion compared to $1.0 billion in Q2 2023. This was driven by lower operating expenses (excluding a $525 million legal settlement in Q2 2023) and higher revenues.
- YTD Loss Drivers: The six-month period resulted in a net loss of $2.6 billion, a reversal from the $2.1 billion profit in the prior year. This was primarily due to:
- Acquired IPR&D Expense: A $3.9 billion charge related to the acquisition of CymaBay Therapeutics (March 2024).
- IPR&D Impairment: A $2.4 billion partial impairment charge related to the Trodelvy (sacituzumab govitecan-hziy) asset for non-small cell lung cancer (NSCLC) following Phase 3 study results.
- Equity Securities: Higher net unrealized losses on equity securities.
- Expense Reductions: Selling, general, and administrative (SG&A) expenses decreased 26% in Q2 and 13% YTD, largely due to the absence of the $525 million HIV antitrust litigation settlement recorded in 2023.
Guidance, Outlook, and Risks
- Acquisitions and Pipeline: Gilead completed the acquisition of CymaBay Therapeutics for $3.9 billion net cash, adding seladelpar (for primary biliary cholangitis) to its portfolio. The FDA has accepted the New Drug Application for priority review with a target action date of August 14, 2024.
- Clinical Developments:
- Trodelvy (NSCLC): The Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival, triggering the $2.4 billion impairment charge. The company continues to evaluate Trodelvy in other indications.
- Trodelvy (Urothelial Cancer): The Phase 3 TROPiCs-04 confirmatory study did not meet its primary endpoint, and there were higher deaths due to adverse events compared to the control arm.
- Magrolimab: Development in hematologic cancers was discontinued in February 2024.
- Legal and Regulatory Risks:
- Patent Litigation: Ongoing litigation regarding PrEP patents with the U.S. government (Gilead won a jury verdict in March 2024, government appealed in July 2024). Generic challenges to Biktarvy, Genvoya, and Symtuza are pending with trials scheduled for 2025.
- Antitrust: Phase I of the HIV antitrust class action resulted in a verdict for Gilead; plaintiffs have appealed. Phase II is stayed pending the appeal.
- Product Liability: Approximately 25,000 active plaintiffs in lawsuits alleging kidney, bone, and tooth injuries from Viread/Truvada. A settlement of up to $40 million is in principle for a subset of plaintiffs.
- Capital Allocation: The company repurchased $500 million of common stock YTD and paid $2.0 billion in dividends. A quarterly dividend of $0.77 per share was declared for Q3 2024.
Investor Verification Checklist
- Impairment Impact: Verify the long-term impact of the $2.4 billion Trodelvy NSCLC impairment on future R&D strategy and asset valuation.
- CymaBay Integration: Monitor the regulatory approval timeline for seladelpar (target August 2024) and the commercialization strategy post-acquisition.
- Patent Expiry: Track the status of generic challenges for core HIV products (Biktarvy, Genvoya) and the outcome of the U.S. government PrEP patent appeal.
- Cash Flow Sustainability: Assess the impact of the $3.3 billion decrease in cash and cash equivalents on future capital allocation and debt servicing capabilities.
- Legal Exposure: Review the potential financial exposure from the HIV antitrust appeal and the product liability class actions involving Viread/Truvada.